September 29, 2016 / 11:17 AM / a year ago

BRIEF-Galena biopharma - currently enrolling HER2 1+ and 2+ node positive

Sept 29 (Reuters) - Galena Biopharma Inc :

* Currently enrolling HER2 1+ and 2+ node positive, high-risk node negative patients to study NeuVax in combination with trastuzumab Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below